These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 20127949

  • 1. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L, Nilsson R, Ohlsson T, Sjögren HO, Strand SE, Tennvall J.
    Cancer; 2010 Feb 15; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [Abstract] [Full Text] [Related]

  • 2. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 3. Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
    Mårtensson L, Nilsson R, Ohlsson T, Sjögren HO, Strand SE, Tennvall J.
    J Nucl Med; 2007 Feb 01; 48(2):269-76. PubMed ID: 17268025
    [Abstract] [Full Text] [Related]

  • 4. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb 01; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 5. Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model.
    Nilsson R, Mårtensson L, Eriksson SE, Sjögren HO, Tennvall J.
    Cancer; 2010 Feb 15; 116(4 Suppl):1033-42. PubMed ID: 20127954
    [Abstract] [Full Text] [Related]

  • 6. Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
    Nilsson R, Eriksson SE, Sjögren HO, Tennvall J.
    Acta Oncol; 2011 Jun 15; 50(5):711-8. PubMed ID: 21214493
    [Abstract] [Full Text] [Related]

  • 7. Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE, Ohlsson T, Nilsson R, Tennvall J.
    Cancer Biother Radiopharm; 2012 Mar 15; 27(2):134-40. PubMed ID: 22229635
    [Abstract] [Full Text] [Related]

  • 8. The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
    Örbom A, Eriksson SE, Elgström E, Ohlsson T, Nilsson R, Tennvall J, Strand SE.
    J Nucl Med; 2013 Aug 15; 54(8):1404-10. PubMed ID: 23804328
    [Abstract] [Full Text] [Related]

  • 9. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC.
    J Nucl Med; 2004 Jul 15; 45(7):1224-32. PubMed ID: 15235070
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
    Almqvist Y, Steffen AC, Tolmachev V, Divgi CR, Sundin A.
    Nucl Med Biol; 2006 Nov 15; 33(8):991-8. PubMed ID: 17127172
    [Abstract] [Full Text] [Related]

  • 11. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 15; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 12. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH.
    J Nucl Med; 2005 May 15; 46(5):850-8. PubMed ID: 15872360
    [Abstract] [Full Text] [Related]

  • 13. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM, Memtsoudis S, Vougioukas V, Liersch T, Gratz S, Schmidt F, Lorf T, Post S, Wörmann B, Hiddemann W, Ringe B, Becker W.
    Anticancer Res; 1999 May 15; 19(4A):2427-32. PubMed ID: 10470170
    [Abstract] [Full Text] [Related]

  • 14. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody.
    Garkavij M, Tennvall J, Strand SE, Sjögren HO, JianQing C, Nilsson R, Isaksson M.
    J Nucl Med; 1997 Jun 15; 38(6):895-901. PubMed ID: 9189138
    [Abstract] [Full Text] [Related]

  • 15. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
    Mårtensson L, Wang Z, Nilsson R, Ohlsson T, Senter P, Sjögren HO, Strand SE, Tennvall J.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 2):7104s-7108s. PubMed ID: 16203809
    [Abstract] [Full Text] [Related]

  • 16. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
    Vera DR, Eigner S, Beran M, Henke KE, Laznickova A, Laznicek M, Melichar F, Chinol M.
    Cancer Biother Radiopharm; 2011 Jun 01; 26(3):287-97. PubMed ID: 21711096
    [Abstract] [Full Text] [Related]

  • 17. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
    Lindén O, Kurkus J, Garkavij M, Cavallin-Ståhl E, Ljungberg M, Nilsson R, Ohlsson T, Sandberg B, Strand SE, Tennvall J.
    Cancer Biother Radiopharm; 2005 Aug 01; 20(4):457-66. PubMed ID: 16114994
    [Abstract] [Full Text] [Related]

  • 18. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.
    Clin Cancer Res; 2002 Sep 01; 8(9):2806-11. PubMed ID: 12231520
    [Abstract] [Full Text] [Related]

  • 19. A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats.
    Mårtensson L, Nilsson R, Sjögren HO, Strand SE, Tennvall J.
    Artif Organs; 2007 Apr 01; 31(4):312-6. PubMed ID: 17437500
    [Abstract] [Full Text] [Related]

  • 20. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.